YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF vs ResMed Inc. — how do they compare? YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF trades at $40.02, while ResMed Inc. trades at $193.21 (market cap $28.40B). The key difference: ResMed Inc. pays a 1.23% dividend while YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF pays none, and YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF is trading nearer its 52-week high, ResMed Inc. nearer its low. Which is the better fit depends on your goals.
| QDTY | RMD | |
|---|---|---|
Sector | Income / Options Overlay | Health |
52-Week High | $46.71 | $293.73 |
52-Week Low | $36.57 | $182.82 |
Market Cap | — | $28.40B |
Enterprise Value | — | $27.58B |
Dividend Yield | — | 1.23% |
Signals from Pluang's Aura AI — not financial advice
QDTY trades at $39.53 with minimal daily movement (+0.15%). Technical indicators show a bearish trend with moving averages signaling strong selling pressure, while oscillators remain neutral. The stock faces immediate resistance at $40 and support at $39. Recent corporate actions include consistent weekly dividend distributions, with amounts ranging from $0.22 to $0.32 per share throughout 2026.
The outlook remains cautious given the bearish technical signals and lack of available fundamental data. While the consistent dividend payments provide some income stability, the absence of key financial metrics like P/E ratio and profitability measures limits fundamental analysis. Investors face uncertainty regarding the company's financial health and growth prospects without current earnings data.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
QDTY is an actively managed ETF that employs a synthetic covered call strategy on the Nasdaq-100 Index using zero-days-to-expiration (0DTE) options. It aims to generate high weekly income by selling daily call options, providing limited participation in the index's upside while remaining fully exposed to its downside risk.
Read more on QDTY →ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →